Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Singh

Showing results (301-310 of 505) with videos related to

Pageof 51
Sort By:
Therapeutic Advances in Respiratory Disease|July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factorsDave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Research|January 10, 2019
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME studyJadwiga A Wedzicha, Dave Singh, Ioanna Tsiligianni, et al.
Respiratory Research|July 11, 2020
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trialKlaus F Rabe, David M G Halpin, MeiLan K Han, et al.
Clinical Science (London, England : 1979)|April 1, 2020
Effects of corticosteroids on COPD lung macrophage phenotype and functionAndrew Higham, Tom Scott, Jian Li, et al.
Thorax|December 16, 2025
Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trialAlexander G Mathioudakis, Sebastian Bate, Victoria Chatzimavridou-Grigoriadou, et al.
ERJ Open Research|December 17, 2025
Short-acting β<sub>2</sub>-agonist use, exacerbation risk and triple therapy in COPD: <i>post hoc</i> analyses of ETHOSJohn R Hurst, Dave Singh, Fernando J Martinez, et al.
Therapeutic Advances in Respiratory Disease|February 15, 2018
Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary diseaseFrançois Maltais, Denis O'Donnell, Juan Bautista Gáldiz Iturri, et al.
Respiratory Research|March 24, 2021
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trialJinping Zheng, Simonetta Baldi, Li Zhao, et al.
ERJ Open Research|June 1, 2019
High frequency of infection of lung cancer patients with the parasite <i>Toxoplasma gondii</i>Jaroslav Bajnok, Muyassar Tarabulsi, Helen Carlin, et al.
The European Respiratory Journal|September 20, 2014
Characterisation and impact of reported and unreported exacerbations: results from ATTAINPaul W Jones, Rosa Lamarca, Ferran Chuecos, et al.
Pageof 51

Showing results (301-310 of 505) with videos related to

Sort By:
Pageof 51
Therapeutic Advances in Respiratory Disease|July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factorsDave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Research|January 10, 2019
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME studyJadwiga A Wedzicha, Dave Singh, Ioanna Tsiligianni, et al.
Respiratory Research|July 11, 2020
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trialKlaus F Rabe, David M G Halpin, MeiLan K Han, et al.
Clinical Science (London, England : 1979)|April 1, 2020
Effects of corticosteroids on COPD lung macrophage phenotype and functionAndrew Higham, Tom Scott, Jian Li, et al.
Thorax|December 16, 2025
Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trialAlexander G Mathioudakis, Sebastian Bate, Victoria Chatzimavridou-Grigoriadou, et al.
ERJ Open Research|December 17, 2025
Short-acting β<sub>2</sub>-agonist use, exacerbation risk and triple therapy in COPD: <i>post hoc</i> analyses of ETHOSJohn R Hurst, Dave Singh, Fernando J Martinez, et al.
Therapeutic Advances in Respiratory Disease|February 15, 2018
Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary diseaseFrançois Maltais, Denis O'Donnell, Juan Bautista Gáldiz Iturri, et al.
Respiratory Research|March 24, 2021
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trialJinping Zheng, Simonetta Baldi, Li Zhao, et al.
ERJ Open Research|June 1, 2019
High frequency of infection of lung cancer patients with the parasite <i>Toxoplasma gondii</i>Jaroslav Bajnok, Muyassar Tarabulsi, Helen Carlin, et al.
The European Respiratory Journal|September 20, 2014
Characterisation and impact of reported and unreported exacerbations: results from ATTAINPaul W Jones, Rosa Lamarca, Ferran Chuecos, et al.
Pageof 51